Draxis files for Canadian approval

Draxis (TSE:DAX; DRAX) filed for Canadian marketing approval of Zonegran zonisamide as an adjunct treatment for epileptic seizures. Zonegran is marketed in Japan and the U.S. The product was in-licens...